The future of combination immunotherapy in oesophageal adenocarcinoma

Overview of attention for article published in Frontiers in immunology, July 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (59th percentile)
Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter: 5 X users

Readers on

mendeley: 3 Mendeley

Summary X

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 49,463 followers.

The future of combination immunotherapy in oesophageal adenocarcinoma https://t.co/eocN16n4l0 https://t.co/UqS4for7KF

31 Jul 2023

Reply Repost Favourite

RT @manuelmuro5: Están en curso varios ensayos que prueban la eficacia de anti-PD-1 como un enfoque de punto de control dual con inmunotera…

16 Jul 2023

Reply Repost Favourite

RT @manuelmuro5: Están en curso varios ensayos que prueban la eficacia de anti-PD-1 como un enfoque de punto de control dual con inmunotera…

16 Jul 2023

Reply Repost Favourite

Están en curso varios ensayos que prueban la eficacia de anti-PD-1 como un enfoque de punto de control dual con inmunoterapias combinadas novedosas como anti-TIGIT, anti-LAG-3 o anti-TIM-3, para beneficiar a los pacientes con adenocarcinoma de esófago. htt

16 Jul 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.